CliffBio

Bristol-Myers Squibb Company

Patent cliffs & loss of exclusivity

Company

Company Operating StatusActive
Facebook URLhttp://www.facebook.com/bristolmyerssquibb
Instagram URLhttps://www.instagram.com/bristolmyerssquibb
LinkedIn URLhttp://www.linkedin.com/company/bristol-myers-squibb
Twitter URLhttps://twitter.com/univkyoto
Official Websitehttps://bms.com/jp

12 upcoming patent cliffs

DrugIngredientTypeCliff
  1. OrenciaabataceptBiologicDec 2017
  2. YervoyipilimumabBiologicMar 2023
  3. YervoyipilimumabBiologicMar 2023
  4. NulojixbelataceptBiologicJun 2023
  5. OrenciaabataceptBiologicJul 2023
  6. OpdivonivolumabBiologicDec 2026
  7. OpdivonivolumabBiologicDec 2026
  8. EmplicitielotuzumabBiologicNov 2027
  9. EmplicitielotuzumabBiologicNov 2027
  10. OrenciaabataceptBiologicJun 2028
  11. OrenciaabataceptBiologicMar 2029
  12. OrenciaabataceptBiologicMar 2029
  13. OpdivonivolumabBiologicOct 2029
  14. OpdivonivolumabBiologicAug 2033
  15. Opdualagnivolumab and relatlimab-rmbwBiologicMar 2034
  16. Opdivo Qvantignivolumab and hyaluronidase-nvhyBiologicDec 2036
  17. Opdivo Qvantignivolumab and hyaluronidase-nvhyBiologicNov 2037

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.

Bristol-Myers Squibb Company — patent cliffs & loss of exclusivity | CliffBio